Experts involved in its development are confident the agent has the potential to overcome shortcomings associated with conventional oral agents currently on the market.
Extravascular ICDs were developed to avoid complications such as vascular injuries, lead fractures and lead infections. Although rare, these issues can cause serious, life-threatening complications for patients.
The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment.
The randomized, double-blinded phase 3 study revealed gadopiclenol to be noninferior to gadobutrol for all qualitative visualization parameters as rated by all blinded readers involved in the trial.
Researchers at the National Institute of Standards and Technology (NIST) are working on developing measurements that will provide better insight into soft tissue properties visualized on portable MRI images.
The program leverages the in-context learning abilities of large language models to generate report summaries using domain-specific, individualized data relative to radiology.
The FDA Circulatory System Devices Panel is set to review the PMA submissions for the ReCor and Medtronic renal denervation systems to treat patients with uncontrolled hypertension.
Jonathan Lindner, MD, offers an update on the use of echocardiography and bubble contrast agents in a therapy role to help revascularize STEMI patients and increase drug and gene delivery.
